Documents

Strong revenue and EBITDA growth driven by India outperformance and JB merger synergies.

Q4 revenue surged 42% with robust India and Brazil growth, and semaglutide launch outperformed.

Q3 FY26 delivered double-digit growth, JB integration progressing, and cost synergies targeted.

Double-digit growth in India and Brazil drove 14% revenue rise; Germany lagged on supply issues.

Double-digit growth in India and Brazil, with stable margins and ongoing expansion.

Q4 delivered robust growth in India and U.S., with strong margins and focus on debt reduction.

India and Brazil drive growth; margin improvement and debt reduction on track.

Q2 saw robust branded business growth, margin expansion, and strong India and Brazil performance.

Strong Q1 growth driven by India and Brazil, with margin expansion and positive outlook.